Hal Hirte

Hal Hirte

UNVERIFIED PROFILE

Are you Hal Hirte?   Register this Author

Register author
Hal Hirte

Hal Hirte

Publications by authors named "Hal Hirte"

Are you Hal Hirte?   Register this Author

56Publications

1303Reads

26Profile Views

Expanded CD56CD16 NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model.

Cancer Immunol Res 2018 10 17;6(10):1174-1185. Epub 2018 Jul 17.

Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0144DOI Listing
October 2018

Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.

Cancer Immunol Immunother 2018 Apr 3;67(4):575-587. Epub 2018 Jan 3.

Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Rm 4015 Michael DeGroote Centre for Learning and Discovery, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2112-xDOI Listing
April 2018

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

N Engl J Med 2017 03;376(11):1027-1037

From Odette Cancer Centre, Sunnybrook Health Sciences Centre (J.R.P., A.S.) and Princess Margaret Cancer Centre (N.L., W.P.M.), Toronto, the Canadian Cancer Trials Group, Queens University, Kingston, ON (C.J.O., C.W., K.D.), University of Calgary, Calgary, AB (J.G.C.), University of Alberta, Edmonton (W.R.), Quality of Life Consulting, West Vancouver, BC (D.O.), Queen's University, Kingston General Hospital, Kingston, ON (J.P.R.), and Juravinski Cancer Centre, Hamilton, ON (H.H.) - all in Canada; Azienda Unità Sanitaria Locale- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche, Bologna (A.A.B., E.F.), and Fondazione Istituto Neurologico Carlo Besta, Milan (L. Fariselli) - both in Italy; University Hospital Gasthuisberg, Leuven, Belgium (J.M.); Peter MacCallum Cancer Centre, Melbourne, VIC (C.P.), University of Newcastle, Newcastle, NSW (M.F.), University of Queensland, Brisbane (M.F.), and Royal North Shore Hospital, Sydney (M.B.) - all in Australia; Saitama Medical University International Medical Center, Saitama, Japan (R.N.); Hôpital de la Pitié-Salpêtrière (F.L.-D., L. Feuvret), Paris, and Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire Timone, Marseilles (O.C.) - both in France; the European Organization for Research and Treatment of Cancer, Brussels (V.G.); the Neurology Clinic, University of Heidelberg, Heidelberg, Germany (A.W., W.W.); Tauranga Hospital, Tauranga, New Zealand (M.T.); and Maastricht University Medical Center and School for Oncology and Developmental Biology, Maastricht, the Netherlands (B.G.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611977DOI Listing
March 2017

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

J Clin Oncol 2016 12 23;34(36):4345-4353. Epub 2016 Oct 23.

Joyce F. Liu, Dana-Farber Cancer Institute, Boston; Isabelle Tabah-Fisch and Joseph Pearlberg, Sanofi Oncology; Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, and Gavin MacBeath, Merrimack Pharmaceuticals, Cambridge, MA; R. Wendel Naumann, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, Houston, TX; Isabelle Ray-Coquard, Centre Léon Bérard, University Claude Bernard, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Lyon; Frederic Selle, Hôpital Tenon and GINECO; Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Université Paris Descartes, and GINECO, Paris; Laurence Gladieff, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole, and GINECO, Toulouse, France; Andrés M. Poveda, Instituto Valenciano de Oncologia and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia; Josep Maria del Campo, Hospital Universitari Vall d'Hebron and GEICO, Barcelona, Spain; David Cibula, General University Hospital Prague and Charles University, Prague, Czech Republic; Hal Hirte, Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario, Canada; Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Kiel; Philipp Harter, Kliniken Essen Mitte and Arbeitsgemeinschaft Gynäkologische Onkologie, Essen, Germany; Francesco Raspagliesi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori; Salvatore Siena, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milano, Italy; and Ignace Vergote, University Hospital Katholieke Universiteit Leuven and Leuven Cancer Institute, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1891DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562430PMC
December 2016

A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.

Invest New Drugs 2014 Dec 19;32(6):1226-35. Epub 2014 Jul 19.

Cross Cancer Centre, 11560 University Ave NW, Edmonton, Alberta, T6G 1Z2, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0139-9DOI Listing
December 2014

Management of advanced or recurrent cervical cancer: chemotherapy and beyond.

Expert Rev Anticancer Ther 2014 Mar 10;14(3):319-32. Epub 2014 Jan 10.

Department of Obstetrics and Gynecology, 699 Concession Street, McMaster University, Hamilton, ON, L9G 2Z8 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2014.866041DOI Listing
March 2014

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Invest New Drugs 2013 Oct 17;31(5):1182-91. Epub 2013 Jul 17.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Avenue, 5-125, M5G 2M9, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-013-0001-5
Publisher Site
http://dx.doi.org/10.1007/s10637-013-0001-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771370PMC
October 2013

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.

Authors:
Hal W Hirte

Onco Targets Ther 2013 18;6:427-35. Epub 2013 Apr 18.

Department of Oncology, McMaster University, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S30373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665572PMC
June 2013

Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.

Onco Targets Ther 2013 26;6:107-18. Epub 2013 Feb 26.

Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada ; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S30238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585576PMC
March 2013

Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent.

Clin Biochem 2009 Jul 21;42(10-11):1162-5. Epub 2009 Apr 21.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000991200900188
Publisher Site
http://dx.doi.org/10.1016/j.clinbiochem.2009.04.008DOI Listing
July 2009

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

J Clin Oncol 2009 Jul 18;27(19):3097-103. Epub 2009 May 18.

MD (Lon), FRCPC, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Ave 5-700, Toronto, Ontario, Canada, M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.20.4826DOI Listing
July 2009

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

Clin Cancer Res 2008 Jun;14(11):3450-5

Juravinski Cancer Centre at Hamilton Health Sciences, 699 Concession Street, Hamilton, Ontario, Canada L8V 5C2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1416DOI Listing
June 2008

Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies.

Clin Biochem 2008 May 7;41(7-8):607-10. Epub 2008 Feb 7.

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2008.01.019DOI Listing
May 2008

Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.

J Clin Oncol 2008 Mar;26(8):1324-30

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Ste 5-718, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.0673DOI Listing
March 2008

An optimized clinical regimen for the oncolytic virus PV701.

Clin Cancer Res 2007 Feb;13(3):977-85

Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1817DOI Listing
February 2007

Immuno-isolation in cancer gene therapy.

Curr Gene Ther 2006 Apr;6(2):181-91

Department of Biology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156652306776359513DOI Listing
April 2006

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

Curr Pharm Des 2002 ;8(25):2249-53

Department of Medicine, McMaster University and Division of Medical Oncology, Hamilton Regional Cancer Centre, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612023393053DOI Listing
March 2003

Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer.

Curr Opin Obstet Gynecol 2002 Feb;14(1):67-73

Division of Gynecologic Oncology, MacMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001703-200202000-00011DOI Listing
February 2002

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

Gynecol Oncol 2002 Feb;84(2):327-31

National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2001.6409DOI Listing
February 2002